CO6410289A2 - Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis - Google Patents

Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis

Info

Publication number
CO6410289A2
CO6410289A2 CO11116668A CO11116668A CO6410289A2 CO 6410289 A2 CO6410289 A2 CO 6410289A2 CO 11116668 A CO11116668 A CO 11116668A CO 11116668 A CO11116668 A CO 11116668A CO 6410289 A2 CO6410289 A2 CO 6410289A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
prevention
control
tuberculosis treatment
Prior art date
Application number
CO11116668A
Other languages
English (en)
Spanish (es)
Inventor
Jerome B Zeldis
Gilla Kaplan
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410289(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CO6410289A2 publication Critical patent/CO6410289A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO11116668A 2009-02-10 2011-09-09 Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis CO6410289A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15146709P 2009-02-10 2009-02-10

Publications (1)

Publication Number Publication Date
CO6410289A2 true CO6410289A2 (es) 2012-03-30

Family

ID=42077260

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11116668A CO6410289A2 (es) 2009-02-10 2011-09-09 Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis

Country Status (23)

Country Link
US (1) US20120149716A1 (https=)
EP (2) EP2395995A1 (https=)
JP (2) JP2012517441A (https=)
KR (1) KR20110116049A (https=)
CN (1) CN102387798A (https=)
AP (1) AP3437A (https=)
AU (1) AU2010213936B2 (https=)
BR (1) BRPI1007500A2 (https=)
CA (1) CA2750123A1 (https=)
CO (1) CO6410289A2 (https=)
CR (1) CR20110411A (https=)
EA (1) EA201171035A1 (https=)
EC (1) ECSP11011295A (https=)
HK (1) HK1205681A1 (https=)
IL (1) IL214176A (https=)
MX (1) MX2011008132A (https=)
MY (1) MY160002A (https=)
NI (1) NI201100154A (https=)
NZ (1) NZ594193A (https=)
PE (2) PE20120580A1 (https=)
SG (2) SG173149A1 (https=)
UA (1) UA103791C2 (https=)
WO (1) WO2010093588A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6143675B2 (ja) 2010-12-16 2017-06-07 セルジーン コーポレイション 難溶性薬物の制御放出経口剤形及びその使用
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
RS60415B1 (sr) 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
WO2013119607A2 (en) * 2012-02-08 2013-08-15 Celgene Corporation Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US10011611B2 (en) 2015-08-14 2018-07-03 Reaction Biology Corp. Histone deacetylase inhibitors and methods for use thereof
WO2017070291A1 (en) * 2015-10-21 2017-04-27 Celgene Corporation Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
DE102018201827A1 (de) * 2017-02-28 2018-08-30 Aktiebolaget Skf Wälzlager
CN112220785B (zh) * 2020-09-22 2021-12-31 北京鑫开元医药科技有限公司 一种pde4抑制剂药物组合物及其制备方法与用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
DE69503769T2 (de) * 1994-03-09 1998-12-03 Pfizer Inc., New York, N.Y. Isoxazoline verbindung zur hemmung tnf-freigabe
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
NZ334148A (en) 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
HUP0003761A3 (en) 1997-07-31 2001-04-28 Celgene Corp Warren Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
KR100620404B1 (ko) * 2000-08-09 2006-09-13 파나세아 바이오테크 리미티드 항결핵 약물의 신규 약제학적 조성물 및 그의 제조방법
AU2003222034A1 (en) 2002-03-20 2003-10-08 Celgene Corporation (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
TW200501945A (en) * 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
NZ540546A (en) 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
BR0317885A (pt) 2002-12-30 2005-12-06 Celgene Corp Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa
JP2006519874A (ja) 2003-03-05 2006-08-31 セルジーン・コーポレーション ジフェニルエチレン化合物およびその使用
DE602004032522D1 (de) 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
JP4713465B2 (ja) 2003-03-12 2011-06-29 セルジーン コーポレイション ７−アミド−イソインドリル化合物およびその薬学的使用
US7244259B2 (en) 2003-10-31 2007-07-17 Ethicon, Inc. Guide for surgical device for the treatment of urinary incontinence
US7405237B2 (en) 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
KR20070092276A (ko) * 2004-12-13 2007-09-12 셀진 코포레이션 Ｐｄｅ４ 조절인자를 포함하는 조성물 및 이의 기도염의치료 또는 예방을 위한 용도
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AP2011005849A0 (en) 2011-08-31
AU2010213936A1 (en) 2011-08-11
US20120149716A1 (en) 2012-06-14
IL214176A (en) 2016-09-29
JP2012517441A (ja) 2012-08-02
AU2010213936B2 (en) 2014-07-31
HK1205681A1 (en) 2015-12-24
NZ594193A (en) 2013-09-27
SG10201402158VA (en) 2014-07-30
IL214176A0 (en) 2011-08-31
NI201100154A (es) 2012-01-24
WO2010093588A1 (en) 2010-08-19
ECSP11011295A (es) 2011-09-30
MY160002A (en) 2017-02-15
PE20151143A1 (es) 2015-08-07
BRPI1007500A2 (pt) 2016-02-16
MX2011008132A (es) 2011-09-06
AP3437A (en) 2015-10-31
CA2750123A1 (en) 2010-08-19
EA201171035A1 (ru) 2012-02-28
CN102387798A (zh) 2012-03-21
UA103791C2 (uk) 2013-11-25
SG173149A1 (en) 2011-08-29
KR20110116049A (ko) 2011-10-24
PE20120580A1 (es) 2012-05-23
JP2015164928A (ja) 2015-09-17
EP2395995A1 (en) 2011-12-21
EP2818164A1 (en) 2014-12-31
CR20110411A (es) 2012-01-06

Similar Documents

Publication Publication Date Title
CO6410289A2 (es) Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
MX2015005879A (es) Formulaciones de capsaicinoides basadas en agua, y tratamiento en combinacion con un corticosteroide.
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
MX2017016774A (es) Agente terapeutico para la fibrosis.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX384159B (es) Formulaciones y métodos para el suministro vaginal de antiprogestinas.
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
MX2016005510A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
MX2016009226A (es) Combinaciones farmaceuticas.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
HK1164716A (en) Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis

Legal Events

Date Code Title Description
FC Application refused